Reports Q3 revenue $285M, consensus $278.58M. “I am pleased we achieved both top- and bottom-line growth for the third-quarter,” said CEO Michael B. Petras, Jr. “Our performance was largely in line with expectations, with an additional benefit at Nordion tied to the timing of cobalt-60 shipments. With most of the year behind us, we are reaffirming the 2024 revenue and EBITDA outlook ranges previously provided. “We are also excited to host our inaugural investor day on November 20th, which will take place in New York City. During the event, the management team will present a business and financial review, including future growth plans, while highlighting how we fulfill our mission of Safeguarding Global Health.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SHC:
- SHC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Sotera Health Board Changes and Shareholder Stock Sale
- Verizon making $20B fiber buy, Topgolf and Fortive splitting up: Morning Buzz
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
